Budget impact analysis of pneumococcal conjugate vaccines in Colombia. Response to letter to the editor

"Budget impact analysis of pneumococcal conjugate vaccines in Colombia. Response to letter to the editor." Expert Review of Pharmacoeconomics & Outcomes Research, 22(1), pp. 5–6

Acknowledgments

The authors thank Business & Decision Life Sciences platform (on behalf of GSK) for editorial assistance, manuscript coordination and writing support. Pierre-Paul Prevot coordinated the manuscript development and editorial support.

Declaration of interests

Jorge A. Gomez, Diana Caceres and Edisson Rodriguez are employees of GSK group of companies. Jorge A. Gomez and Diana Caceres holds shares in GSK group of companies. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Editor disclosures

The editor who approved this letter for publication has no relevant financial relationships or otherwise to disclose.

Additional information

Funding

GlaxoSmithKline Biologicals SA (HO-19-20065) funded all costs associated with the development of this publication.